Induction of human leukocyte antigen-A26-restricted and tumor-specific cytotoxic T lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes

Journal of Immunotherapy

Volumn 23, Issue 3, 2000, Pages 296-303

  Inoue, Yoshiko ^a   Nakao, Masanobu ^a   Matsunaga, Kazuko ^a   Kikuchi, Megumi ^a   Gomi, Shinya ^b   Toh, Uhi ^b   Takamori, Shinzo ^a   Yamana, Hideaki ^b   Itoh, Kyogo ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccine; Cytotoxic T lymphocytes; HLA A26 subtype; Peptide; SART1 antigen

Indexed keywords

CANCER VACCINE; EPITOPE; HLA ANTIGEN; PEPTIDE;

ANTIGEN EXPRESSION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ESOPHAGUS CANCER; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTIGENS, NEOPLASM; CYTOTOXICITY TESTS, IMMUNOLOGIC; HLA-A ANTIGENS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; RIBONUCLEOPROTEINS, SMALL NUCLEAR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034119123     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200005000-00002     Document Type: Article

References (24)

1. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-7.
2. van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-43.
3. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
4. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
5. Kang X, Kawakami Y, El-Gamil M, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995;155:1343-8.
6. Robbins PF, El-Gamil M, Li YF, et al. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
7. Robbins PF, El-Gamil M, Li YF, et al. The intronic region of an incompletely spliced gplOO gene transcript encodes anepitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 1997;159:303-8.
8. Robbins PF, El-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154 5944-50.
9. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-5.
10. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4: 321-7.
11. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
12. Mandruzzato A, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytotoxic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-93.
13. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellularimmune response against cancer-testis antigen NY-ESO1-1: definition of human histocompatibility leukocyte antigen HLA-A2-binding peptide epitope. J Exp Med 1998;18:265-70.
14. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T ymphocytes. J Exp Med 1998;187:277-88.
15. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and Haplotvpe Frequencies for HLA and Complement Loci in Various Ethnic Groups. Oxford, UK: Oxford Scientific Publications, 1992, pp 1065-1220.
16. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: Population study and identification of four new alleles in Japanese. Tissue Antigens 1996;47:93-101.
17. Klenerman P, Luzzi G, McIntyre K, Phillips R, Mcmichapl A. Identification of a novel HLA-A25-restricted epitope in a conserved region of p24 gag (positions 71-80). AIDS 1996;10:348-50.
18. Goulder P, Conlon K, McIntyre K, McMichael A. Identification of a novel human leukocyte ntigen A26 restricted epitope in a conserved region of Gag. AIDS 1996;10:1441-3.
19. Tanigaki N, Fruci D, Chersi A, et al. HLA-A2-bindingpeptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Human Immunol 1994;39:155-62.
20. Ellexson EM, Peck LR, Stewart D, Keller J, Hildebrand WH. Characterization of an HLA-A26 serologic variant. Immunogenetics 1998;48:152-5.
21. Dumrese T, Stevanovic S, Seeger FH, et al. HLA-A26 subtype A pockets accommodate acidic N-termini of ligands. Immunogenetics 1998;48:350-3.
22. Kikuchi M, Nakao M, Inoue Y, et al. Identification of a SART-1-derived peptoide capable of inducing the HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 1999;81: 459-66.
23. Kawakami Y, Rosenberg SA. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1996;15:179-90.
24. Mastumoto H, Shichijo S, Kawano K, et al. Expression of the SART-1 antigens in uterine cancers. Jpn J Cancer Res 1998;89: 1292-5.